Loading company…
Seoul-based developer of in vitro and companion diagnostic products for hereditary breast and ovarian cancer.
Founded in 2015 and based in Seoul, South Korea, NGeneBio develops in vitro diagnostics (IVD) and companion diagnostics (CDx) products for hereditary breast and ovarian cancer. In December 2020 it raised KRW 34.216 billion in an IPO, selling 2.444 million shares at KRW 14,000 per share on KOSDAQ.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in